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Abstract: Several investigations have suggested that abnormalities in glutamate neural transmission play a role in the 
pathophysiology of psychiatric disorders, including schizophrenia. The metabotropic glutamate 3 receptor (mGluR3) gene 
was reported to be associated with schizophrenia, and paranoid type schizophrenia has symptoms that are similar to those 
of methamphetamine-induced psychosis. This suggests that mGluR3 gene (GRM3) is a good candidate gene for the 
pathogenesis of methamphetamine-induced psychosis. To evaluate the association between GRM3 and methamphetamine-
induced psychosis, we conducted a case-control study of Japanese samples (181 methamphetamine-induced psychosis and 
232 controls).  
Methods: We selected one functional SNP (rs6465084), reported to be associated with prefrontal brain functioning, for an 
association analysis. Written informed consent was obtained from each subject. This study was approved by the ethics 
committees at Fujita Health University, Nagoya University Graduate School of Medicine and each participating member 
of the Institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA).  
Results: We did not detect an association between rs6465084 in GRM3 and Japanese methamphetamine-induced psychosis.  
Conclusion: Our findings suggest that rs6465084 in GRM3 does not play a major role in the pathophysiology of metham-
phetamine-induced psychosis in the Japanese population. However, because we did not perform an association analysis 
based on linkage disequilibrium (LD) or a mutation scan of GRM3, a replication study using a larger sample and based on 
LD may be required for conclusive results. 
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1.INTRODUCTION 
  The glutamate hypothesis is one of the prevailing hy-
potheses for the pathophysiology of schizophrenia [1]. Also, 
a recent clinical study showed that LY379268, an agonist of 
metabotropic glutamate 2/3 receptor (mGluR2/3) that is in-
volved in group II mGluR regulate glutamate neurotransmis-
sion through a presynaptic negative regulatory mechanism, 
has an effect on psychotic symptoms in schizophrenia almost 
equivalent to that of olanzapine [1]. 
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  Several investigations have suggested that metabotropic 
glutamate 3 receptor (mGluR3) gene has an association with 
schizophrenia [2-4]. Since the symptoms of methampheta-
mine-induced psychosis are similar to those of paranoid type  
schizophrenia [5], it would seem that the mGluR3 gene 
(GRM3) is a good candidate gene for the pathogenesis of 
methamphetamine-induced psychosis. To evaluate the asso-
ciation between GRM3 and methamphetamine-induced psy-
chosis, we conducted a case-control study of Japanese sam-
ples (181 methamphetamine-induced psychosis patients and 
232 controls). The mGluR3 gene (GRM3 OMIM *601115, 6 
exons in a genomic region spanning 221.763Kb) is at 7q21. 
We selected rs6465084 in GRM3, which is reported to be 
associated with prefrontal brain functioning. Rs6465084 has 
been found to be associated with decreased verbal list learn-No Association Between GRM3 and Japanese Methamphetamine-  Current Neuropharmacology, 2011, Vol. 9, No. 1    161 
ing and verbal fluency [3]. In addition, Egan and colleagues 
reported that the rs6465084 A allele predicted decreased 
levels of N-acetylaspartate in the prefrontal cortex in   
an in vivo study, and suggested that the rs6465084 A allele 
reduced tissue glutamate levels and synaptic abundance   
[3]. 
2. MATERIALS AND METHODS 
2.1. Subjects 
  The subjects in the association analysis were 181 meth-
amphetamine- induced psychosis patients(155 males and 
26females; mean age33.3 ± 11.4) and 232 controls (187males 
and 45females; mean age36.4 ± 11.3). All subjects were un-
related to each other, ethnically Japanese, and lived in the 
central area of Japan. The patients were diagnosed according 
to DSM-IV criteria with consensus of at least two experi-
enced psychiatrists on the basis of unstructured interviews 
and a review of medical records. One hundred thirty-seven 
subjects with METH- induced psychosis also had depend-
ence on drugs other than METH. Subjects with METH-
induced psychosis were excluded if they had a clinical diag-
nosis of psychotic disorder, mood disorder, anxiety disorder 
or eating disorder. More detailed characterizations of these 
subjects have been published elsewhere [6-8]. All healthy 
controls were also psychiatrically screened based on unstruc-
tured interviews including current and past psychiatric his-
tory. None had severe medical complications such as cirrho-
sis, renal failure, heart failure or other Axis-I disorders ac-
cording to DSM-IV. No structured methods were used to 
assess psychiatric symptoms in the controls, which included 
hospital staff, their families and medical students. 
  The study was described to subjects and written informed 
consent was obtained from each. This study was approved by 
the Ethics Committee at Fujita Health University, Nagoya 
University School of Medicine and and each participating 
member of the Institute of the Japanese Genetics Initiative 
for Drug Abuse (JGIDA). 
2.2. SNP Selection 
  We selected rs6465084 in GRM3, which is reported   
to be associated with prefrontal brain functioning, for the 
following association analysis. 
2.3. SNP Genotyping 
  SNP genotyping was done using TaqMan assays   
(Applied Biosystems) [9].  
2.4. Statistical Analysis 
  Genotype deviation from the Hardy-Weinberg equilib-
rium (HWE) was evaluated with the chi-square test (SAS/ 
Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan). 
  Marker-trait association analysis was used to evaluate 
allele- and genotype-wise association with the chi-square test 
(SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan). 
To control inflation of the type I error rate, we used Bonfer-
roni’s correction. Power calculation was performed using a 
statistical program prepared by Purcell et al. 
  The significant level for all statistical tests was 0.05. 
3. RESULTS 
  Rs6465084 is in HWE. We detected no association be-
tween rs6465084 in GRM3 and METH-induced psychosis in 
the allele/genotype-wise analysis (Table 1). 
4. DISCUSSION 
  We performed an association study of rs6465084 in 
GRM3 and METH- induced psychosis in the Japanese popu-
lation. Although, we recently found an association between 
GRM2 and METH- induced psychosis in the Japanese popu-
lation [10], in the present study we detected no association 
between GRM3 with METH-induced psychosis. 
  Egan and colleagues reported that the rs6465084 A allele 
predicted decreased levels of N-acetylaspartate in the pre-
frontal cortex in an in vivo study, and suggested that the 
rs6465084 A allele reduced tissue glutamate levels and syn-
aptic abundance [3]. This influence of GRM3 on prefrontal 
cortex and cognitive function suggests that abnormalities in 
glutamate neurotransmission may be involved in the patho-
physiology of METH- induced psychosis. However, we did 
not detect an association between GRM3 and METH-induced 
psychosis. We designed the present study based on common 
disease–common variants hypothesis (CD–CV hypothesis) 
[11]. In addition, we selected only one SNP in GRM3. A 
recent study has showed an association between common 
diseases such as schizophrenia and rare variants. If the ge-
netic background of METH-induced psychosis is accurately 
described by the common disease-rare variants hypothesis, 
further investigation such as medical resequencing using 
larger samples will be required [8, 12-17]. 
  There are a few limitations in this study. First, the lack of 
association may be due to biased samples, such as small 
sample sizes. Second, we selected only one SNP in GRM3. 
Table 1.  Association Analysis of GRM3 with MAP with Psychosis 
Genotype Distribution  P-Value
c
 
SNP Phenotype
a
 MAF
b
 N 
TT  TC CC  HWE Genotype Allele 
rs6465084  Controls  0.0926  232  193  35  4 0.117 0.153 0.941 
A>G  MAP with psychosis  0.0911  181  148  33  0  0.177     
a MAP with psychosis: methanphetamine use disorder with psychosis 
b MAF: major allele frequency 
c Hardy-Weinberg equilibrium. 162    Current Neuropharmacology, 2011, Vol. 9, No. 1  Tsunoka et al. 
To overcome these limitations, it will be necessary conduct a 
replication study using gene based association analysis and 
larger samples. 
5. CONCLUSION 
  Our results suggest that rs6465084 in GRM3 does might 
not play a role in the pathophysiology of METH-induced 
psychosis in the Japanese population. However, our results 
have limitations and replication study using gene-based 
association analysis and larger samples will be required. 
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